Upgrade to SI Premium - Free Trial

Astellas Pharma Inc Unsponsored Adr (ALPMY)

13.32 -0.28 (2.06%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,300 at JPMorgan June 29, 2026 8:29 AM - StreetInsider Goldman Sachs Reiterates Buy Rating on Astellas Pharma Inc (4503:JP) (ALPMY) June 16, 2026 12:22 AM - StreetInsider Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,600 at Macquarie May 28, 2026 10:37 AM - StreetInsider Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company May 26, 2026 2:45 AM - PR NewsWire Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026 May 18, 2026 8:01 AM - PR NewsWire "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies May 14, 2026 10:55 AM - Globe NewsWire Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study May 12, 2026 9:04 AM - StreetInsider IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients May 12, 2026 9:01 AM - PR NewsWire Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,400 at Citi May 4, 2026 12:59 AM - StreetInsider Astellas Pharma Inc (4503:JP) (ALPMY) PT Lowered to JPY2,400 at Citi May 1, 2026 7:15 AM - StreetInsider Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting April 30, 2026 9:01 AM - PR NewsWire Full Article List